When Bevacizumab Stops Working: — Resistance and What Comes Next

After bevacizumab combined with first-line chemotherapy, NCCN and ESMO guidelines support two broad approaches. The first is continuing bevacizumab but switching the chemotherapy backbone — for example from FOLFOX to FOLFIRI or vice versa. The second is replacing bevacizumab with aflibercept or ramucirumab alongside FOLFIRI. If your tumour is MSI-H, checkpoint immunotherapy becomes a priority at any progression point. A BRAF V600E mutation opens access to a specific targeted combination. Your oncologist will use your RAS, BRAF, and MSI status together to decide the sequence.

In NSCLC treated with bevacizumab plus chemotherapy, progression triggers a full reassessment of the molecular profile. If an EGFR, ALK, ROS1, or other targetable mutation was found at diagnosis, a targeted therapy may have been held for this point in treatment. If not, second-line options most commonly considered under NCCN guidelines include docetaxel with or without ramucirumab, or checkpoint immunotherapy if PD-L1 expression is present. The sequence depends on what was given first-line and what mutations your tumour carries.

Ovarian cancer treated with bevacizumab as part of first-line or maintenance therapy has several subsequent options. PARP inhibitors are relevant if a BRCA mutation or homologous recombination deficiency was identified at diagnosis. Reintroducing platinum-based chemotherapy with or without bevacizumab continued is considered for platinum-sensitive relapse. For platinum-resistant disease, single-agent chemotherapy with or without bevacizumab is among the options outlined in ESMO guidelines. Your gynaecological oncologist will map these options against your specific situation.

Glioblastoma that progresses on bevacizumab is one of the most difficult situations in oncology, and this needs to be said plainly. Published data show that response rates to available agents after bevacizumab progression are low. Options discussed most often include lomustine, temozolomide rechallenge if not previously exhausted, tumour-treating fields, and clinical trial enrolment. A frank conversation with your neuro-oncologist about the goals of any further treatment and about quality of life is an important and legitimate part of this decision, not something to defer.

Bevacizumab used in first-line advanced cervical cancer is typically followed, on progression, by second-line chemotherapy. Pembrolizumab is now recommended by NCCN for PD-L1-positive cervical cancers in subsequent treatment lines. Clinical trials are particularly important to explore here, where the range of established options is more limited than in colorectal or lung cancer. Your oncologist can check the Clinical Trials Registry – India (CTRI) database for active protocols relevant to your diagnosis.

At every progression point, trial eligibility should be explored before committing to a standard second-line regimen. Trials evaluating combinations that block multiple angiogenic pathways simultaneously, or that pair anti-angiogenic agents with immunotherapy, are active in India. The CTRI lists open protocols by diagnosis and treatment site. CION centres discuss clinical trial options as part of second-line planning. A trial may offer access to treatments not otherwise available and should be considered at this stage, not treated as a last resort.